Published in:
01-06-2008 | Others (Announcements, etc.)
Chronic HBV infection with persistently normal ALT b. not to treat
Authors:
Kwang-Hyub Han, Do Young Kim
Published in:
Hepatology International
|
Issue 2/2008
Login to get access
Excerpt
Chronic hepatitis B (CHB) is a lifelong, progressive and potentially fatal disease if not properly treated. Fortunately, successful therapy with antiviral agents resulted in sustained improvements in virologic, biochemical, histologic features of disease and clinical outcome. Although the recent development of a new and potent anti-hepatitis B virus (HBV) agents may offer many therapeutic options against HBV, there are still unsolved issues and areas for the optimal antiviral therapy. The various clinical courses and different status of the diseases, the variable response to antiviral agents, and the lack of long-term outcome of antiviral treatment contribute to the difficulties in establishment of ideal guidelines, particularly in some special patient groups [
1]. It is very important to establish optimal guidelines for whom to treat and when to start, as well as how to treat in Asian patients with CHB. …
